HSTO | Histogen Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0300 - 0.2150
52 Week Range	0.0300 - 0.5500
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	200
Average Volume	533
Shares Outstanding	4,271,760
Market Cap	128,153
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-07-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-2.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

HSTO's peers: AKTX, ALRN, ARTL, CRIS, ENLV, MBIO, PTN, SLRX, VTGN, VYNE, XCUR, IMNN, LSTA

*Chart delayed

Analyzing fundamentals for HSTO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see HSTO Fundamentals page.

Watching at HSTO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HSTO Technicals page.